Is it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS
|
|
- Clare White
- 6 years ago
- Views:
Transcription
1 Is it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS
2 Agenda Annex 1 revision why? Impact of the change on the field Conclusion
3 The Revision of the Annex 1 - aligned with previous EU GMP updates and be harmonized Joint WG PIC/S PI007 (2011) Eur. Ph. WFI US FDA Guide on ASP (2004) USP <1116> PDA TR22 PDA TR13 SITUATION OCT 2016 NON EXHAUSTIVE PIC/S Annex 1 WHO TRS691 Annex 6 (2011) WHO EM for vaccine (2012) JP guide on ASP (2005) EMA guidance on Sterilization (draft) EC annex 15 (2015) EC Annex 1 EC Chapter 3 (2015) EMA guidance on Health based limit (2015) EC Chapter 5 (2015) Structure of the document Revision of the topics: Environmental Monitoring: viable and nonviable Media-simulation Risk assessment and risk management Enforce root cause and product impact Cleaning and disinfection Clean utilities and other Sterilization Cross contamination control Risk Management Monitoring trending New technology
4 The Revision of the Annex 1 - aligned with previous EU GMP updates and be harmonized SITUATION OCT 2016 NON EXHAUSTIVE ISO/TC 209 Clean room and associated controlled environment EN 285 ISO/TC 198 Sterilization of health care products ISO and -2 (2015) IS (2015) AAMI TR52 ISO (2006) ISO ( ) Particle specification Sample number using table NL Risk Assessment: Location Frequency Monitoring Trending Alert and Action limit must be based on trending EC Annex 1 Impact of ISO documents: Environmental Monitoring: viable and nonviable Sterilization management Risk assessment and risk management Cleaning and disinfection Life cycle approach ICH Q9 ICH Q10 ICH Q12
5 Agenda Annex 1 revision why? Future changes and impact on the field Conclusion
6 Impact of ISO and -2: 2015 on non-viable monitoring and control Key changes: Part 1 : Classification specification ISO class 5 Number of sampling and locations Part 2 : Risk Assessment and Management Monitoring plan Frequency Trending (control) Alert and Action Limit based on CpK and assess the frequency for monitoring Guidance about critical parameter monitoring EU and PIC/S annex 1 JP guidance ASP FDA guidance ASP Europe 1 year to implement USA -??
7 Impact of ISO and -2: 2015 on non-viable monitoring and control ISO :1999 ISO :2015 Current EU and PIC/S annex 1; WHO Annex 6 and JP guidance on ASP are not aligned with the ISO 14644
8 Impact of ISO and -2: 2015 on non-viable monitoring and control ISO :1999 ISO :2015 Current EU and PIC/S annex 1; WHO Annex 6 and JP guidance on ASP are not aligned with the ISO Future Annex 1: remove the 5.0 µm for qualification and initial classification but still need to monitor in operation (in routine production) Why still monitor the > 5.0 µm particle: Provide early warning of a potential problem occur In operation is different than at-rest ISO Annex C allow macro-particles monitoring use the terminology e.g.: ISO M (20; 5.0); LSAPC
9 Impact of ISO and -2: 2015 on non-viable monitoring and control ISO :1999 ISO :2015 Table A.1 Sample location related to cleanroom area Surface square of the clean room Important changes on classification and requalification: Impact on the sampling plan Impact on the position and the frequency (Yearly but can be extended if real time monitoring) Scientific approach - based on a risk assessment: Personnel and equipment flow, Operation or position criticality, Smoke studies (grade A, UDF), historical data, etc.
10 Environmental Monitoring and control must be riskbased and scientifically justified The goal of EM is to confirm at-rest and in operation : The environment cleanliness: Air, Surface, People, water, gazes The cleaning and disinfection procedure effectiveness EM plan include : Risk assessment Position Frequency Smoke study Duration QC (media, recovery, incubation) Acceptance Criteria 1 2 DESIGN IMPLEMENT EM Lifecycle approach Implement and Monitor : Measure Gathering data Review and adapt: Acceptance criteria In-house isolate EM plan Cleaning and disinfection People behavior Facility and Process design ACTIONS 4 3 CONTROL Trend and confirm the effectiveness of : EM plan in place Cleaning and Disinfection SOP Define process capability: Upper and Lower contamination Level Atypical results and why?
11 Average for microbial limit would be no more acceptable in Europe, PIC/S and WHO requirements Same microbial limits: EU annex 1 PIC/S annex 1 JP guidance on aseptic processing WHO TR691 annex 6 WHO guidance for vaccine manufacturing Annex 1 (2008) Annex 1 (201X)
12 Microbial recovery rate and incubation program is a key factor for effective monitoring and control plan Recovery and Incubation program may vary depending on the manufacturers process, suppliers, regulatory requirements > Must be scientifically justified! Environmental Monitoring Media simulation Sterility Testing EU PIC/S EU and PIC/S annex 1: N/A PIC/S (2011)**: C min. 7 days C min 7 days US JP WHO Aseptic manufacturing Shopfloor FDA guidance ASP (2004): C for 48-72h C for 5-7 days USP <1116>: C min.72h N/A WHO EM cleanroom in Vaccine Manufacturing (2012)*: C for 3-5 days C for 2-3 days it is a mix depending on several parameters***: - Recovery rate on TSA, SCDA - Environment specificity - Market release FDA guidance ASP (2004) and JP guidance ASP (2006): C at least 14 days (Target+:-2.5 C) If two temperature then min. 7 day each starting with the lower temperature WHO TR691 Annex 6 (2011): N/A it is a mix depending on several parameters***: - Recovery rate on TSA, SCDA - process specificity - Market release EU Ph ; USP <71>; JP <4.0.6> are harmonized: - Temp.: C SCD and C TSA - Time: 14 days incubation *Alternative methods are acceptable when high recoveries (>90%) of microorganisms of interest can be consistently demonstrated. ** Other incubation schedules should be based on supporting validation data. *** different manufacturer has tested at different temperature vs one temperature and shown no difference in recovery rate. This statement is true for some and not for other therefore scientific data must be shown to justify the incubation program [author benchmark]
13 Incubation strategy must be justified based on scientific data and rational for EM and aseptic simulation Gordon O. and all (2014) Roland GM. and all (2016) Sandle T. (2014) Environmental Microorganism Environmental microorganism: Highest recovery: TAC (personnel flow) using TSA and SDA incubated at C Reasonable recovery: TAC (personnel flow) using TSA and SDA incubated at at C Two temperature incubation Environmental Microorganism with TSA SP and CP Highest recovery: 97.7% recovery on SP at 32.5 C 65.4% recovery on CP at 32.5 C Cocci Gram +, non-spore-forming, Grampositive rods > 95% growth and recovery at 32.5 C Environmental Microorganism with TSA recovery: Regime A: C followed by C Regime B: C followed by C No significant difference for TMC between regime A and B Environmental Moulds and yeast Highest recovery: Moulds using TSA and SDA incubated at C Reasonable recovery: Moulds using TSA and SDA incubated at C Two temperature incubation Inneffective recovery: Moulds using TSA and SDA incubated at C Highest recovery: Moulds at 22.5 C alone or as a first temperature incubation No recovery: Strict anaerobes Environmental fungi with TSA recovery: Regime A: C followed by C Regime B: C followed by C Higher indients and number of fungi with the regime B Conclusion 2 samples C aerobic count (in routine) C Moulds (in routine) 2 samples C aerobic count (in routine) C Moulds (periodically) 1 sample C followed by C Source: Gordon O., Berchtold M., Staerk A., Roesti D., Comparison of different incubation conditions for microbiological environmental monitoring, PDA J Pharm Sci Technol.
14 Approach for Cleaning and Disinfection Process and non- Process Equipment INDUSTRY PRACTICE A Soils and microbial Residue type and level A Microbial residue: Is the cleaner agent used efficient B Surface And Equipment Design B Material substrate, area classification, design C C Cleaning and disinfection program based on risk based assessment PDA TR13: it is recommended to periodically review challenge testing of the selected sanitizers, disinfectants and sporicide if representative new isolate are routinely recovered in the EM program Source: Image from McDonnell, Antisepsis, Disinfection, and Sterilization: Types, Action, and Resistance 2007, ASM Press
15 Cleaning and disinfection strategy must be based on the sampling risk level Step 1: Risk Factor determination EXAMPLE Step 2: Risk Factor determination Duration Proximity # People Risk Class Step 3: Design the cleaning and disinfection SOP
16 Disinfectant rotation definition evolution? Eudralex annex 1 (2008) 61. The sanitation of clean areas is particularly important. They should be cleaned thoroughly in accordance with a written programme. Where disinfectants are used, more than one type should be employed. Monitoring should be undertaken regularly in order to detect the development of resistant strains.» FDA guidance on aseptic manufacturing (2004). Routinely used disinfectants should be effective against the normal microbial vegetative flora recovered from the facility.. and Therefore, a sound disinfectant program also includes a sporicidal agent, used according to a written schedule and when environmental data suggest the presence of sporeforming organisms. PIC/S WHO JP guidance on aseptic manufacturing (2006) Cleaning and disinfection of facilities and equipment A program for cleaning and (3) If selected disinfectants might have inferior disinfecting facilities and equipment should be efficacy against microorganisms isolated from established taking into account the potential the environment, the efficacy should be development of drug-resistant microorganisms. reevaluated and the replacement with or The program should contain procedures for alternate use of different disinfectants should be screening and classifying bacterial isolates in each considered and implemented, as appropriate. manufacturing environment.» (4) If environmental monitoring data indicate or suggest the presence of spore-forming bacteria or fungi, suitable sporicides or fungicides should be selected for disinfection. PDA TR70 cleaning and disinfection (2015) USP 39 <1072> disinfectant and antiseptics The rotation of an effective disinfectant with a sporicide is encouraged. It is prudent to augment the daily use of a bactericidal disinfectant with weekly (or monthly) use of a sporicidal agent. The daily application of sporicidal agents is not generally favored because of their tendency to corrode equipment and because of the potential safety issues with chronic operator exposure. Other disinfection rotation schemes may be supported on the basis of a review of the historical environmental monitoring data. However, the most frequently isolated microorganisms from an environmental monitoring program may be periodically subjected to use-dilution testing with the agents used in the disinfection program to confirm their susceptibility, as there are real differences among different species in resistance to the lethal effects of different sanitizers.
17 EU annex 1 and EMA guidance on sterilization (draft) and ISO document aligned or not? Proposed change: EU Annex 1 does not reference the EN 285 or other ISO related to Sterilization processes. However, it is clear that Steam quality and air removal must be performed to demonstrate sterilization process suitability Proposed change: demonstrate sterile integrity of sterilize or RTU packaging before use, e.g. by vacuumed packaged Current Annex 1 and EMA guidance on sterilization require: 113. The integrity of the sterilised filter should be verified before use and should be confirmed immediately after use by an appropriate method such as a bubble point, diffusive flow or pressure hold test. PUPSIT = Post Use Post Sterilization Integrity Test is it mandatory?
18 PUPSIT is it mandatory? Yes, except if the process does not allow a PUPSIT but robust data and adequate risk assessment must demonstrated it. The objective of each filter is important to assess the impact of a failure
19 The goal is to tend to zero contaminated unit during media simulation regardless the number filled. The future annex 1 will ask to tend to zero unit failed during media simulation. Process design must be well developed to avoid non-plus value intervention during aseptic production and simulation. Risk assessment model must be used to assess design effective aseptic manipulation, intervention and assess the risk of failure Intervention with no plus-value must be removed Intervention with high risk of contamination must be avoided Step 1: Risk Factor determination Step 3: Intervention Risk analysis Source Table: Baseman H., Hardiman M., Henkels W., Long M.,2014, Contamination control in Healthcare Product Manufacturing, In: Madsen R. and Moldenhauer J., Contamination Control in Health Care Product Manufacturing, PDA and DHI,Vol.3, p
20 Other changes Structure of the document will change Title will not change and the scope is for aseptic manufacturing Emphasis on EU Dir. 2003/94 article 5 and 2001/83 article 23 Enforce root cause investigation and product impact assessment Process risk assessment and process risk management Personnel training and knowledge Emphasis on keeping the operators away from the product: LABS, RABS, Isolators. Isolators are not mandatory to avoid site closing
21 Other changes Revision WFI monograph: allow the production of WFI by a purification process equivalent to distillation such as reverse osmosis, coupled with appropriate techniques. The revised monograph will be published in the Ph. Eur. Supplement 9.1 and will become effective in April New Section will be added in the Annex 1: Utilities: Compressed air WFI production Biofilms Maybe a possibility for a new document called utilities
22 Factor influencing biofilm generation Biofilm is generally composed of multiple microorganism encased in matrix extracellular polymetric susbstance (EPS): Factor influencing biofilm generation Biofilm generation Conceptual drawing: Biofilm generation
23 Combination of Cleaning Approaches show Effectiveness against Microbial and Biofilm Contamination Combination strategy will be effective against microbial contamination: INDUSTRY BEST PRACTICE 1. Use of alkaline cleaning chemistry: Increase the chemical action Increase the mechanical action 2. Use of the sporicidal chemistry or thermal to disinfect or sterilize the system Fluorescently labeled P. aeruginosa exposed to 5% concentration at 60⁰C: Before exposure biocide (3min) alkaline detergent (6min) P. Aeruginosa Source : STERIS Technical tip
24 Agenda Annex 1 revision why? Future changes and impact on the field Conclusion
25 All processes, program and strategy must be based on effective Risk assessment and design development Environmental monitoring Cleaning and disinfection Cleaning process equipment Media simulation Sterilization Process design People gowning and behavior Etc. 1 2 DESIGN IMPLEMENT Implement and Monitor : Measure Gathering data Lifecycle approach Review and adapt: avoid failure Real time is better ACTIONS 4 3 CONTROL Trend and confirm the effectiveness of : Process capability and performance Assess Alert and Action Limit Define and condirm STV
26 The revision of the annex 1 should reflect the current aseptic practices Are we as good as we think? Number of 483s Issued from the System FY center name Drugs 21.CFR (b) procedure for sterile drug product 21 CFR (b) validation lacking for sterile drug product 21 CFR (c)(10)(iv) Environmental monitoring 21 CFR (c)(10)(v) Cleaning systems 21 CFR (c)(10)(vi) equipment control condition 21 CFR (a) cleaning/sanitization/maintenance 21 CFR (b) written not establish and not followed/followed 21 CFR (b) written procedure failed to include 21 CFR (a) Sterility/pyrogen-free testing FY1015 FY2014 Source:
27 the results of a Belgium Pharmacist Association workshop and questionnaire around the revision of the Annex 1 will be shared during the presentation Participant: 19 pharmaceutical industries Slides will be provided during the presentation.
28 Thank You For your listening El Azab Walid Technical Service Manager STERIS
29 References Note: This is not a complete listing, just a guidance to literature the speaker has found to be interesting/beneficial. European GMP guide to good manufacturing practice for medicinal products annex 1 FDA guidance for industry sterile drug products produced by aseptic processing - current good manufacturing practice WHO annex 6 good manufacturing practices for sterile pharmaceutical products ICH Q9 Quality Risk Management ISO : 2015 Cleanrooms and associated controlled environments -- Part 1: Classification of air cleanliness by particle concentration Gordon O., Berchtold M., Staerk A., Roesti D., Comparison of different incubation conditions for microbiological environmental monitoring, PDA J Pharm Sci Technol. 2014;68(5): Roland GM., Nicole B., Philippe D., Julien T., Mehdi R., Michel T., Philippe B., Christophe A., Edith M., Florine G., Marjorie L., Catherine A., MULTICENTRE STUDY ON INCUBATION PROGRAM FOR ENVIRONMENTAL MONITORING AND ASEPTIC PROCESS SIMULATION, PDA J Pharm Sci Technol Sandle T., Examination of the order of incubation for the recovery of bacteria and fungi from pharmaceutical-grade cleanrooms, Int J Pharm Compd May-Jun;18(3): Baseman H., Hardiman M., Henkels W., Long M.,2014, Contamination control in Healthcare Product Manufacturing, In: Madsen R. and Moldenhauer J., Contamination Control in Health Care Product Manufacturing, PDA and DHI,Vol.3, p USP 39 <1072> disinfectant and antiseptics JP guidance on aseptic manufacturing (2006) PDA TR70 cleaning and disinfection (2015) Baseman H., Hardiman M., Henkels W., Long M.,2014, Contamination control in Healthcare Product Manufacturing, In: Madsen R. and Moldenhauer J., Contamination Control in Health Care Product Manufacturing, PDA and DHI,Vol.3, p
Avoid recurrent microbial contamination using trending of historical data. El Azab Walid Technical Service Manager STERIS
Avoid recurrent microbial contamination using trending of historical data El Azab Walid Technical Service Manager STERIS Agenda Factors influencing the cleaning and disinfection performance Recurring microbial
More informationCase study Microbiological excursion during a phase I PQ of a WFI system. Walid El Azab Technical Service Manager STERIS Life Science
Case study Microbiological excursion during a phase I PQ of a WFI system Walid El Azab Technical Service Manager STERIS Life Science Agenda Agenda Case study Microbiological excursion Description of the
More informationEnvironmental Monitoring of Aseptic Processing Areas - 1
Environmental Monitoring of Aseptic Processing Areas - 1 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1 Training Course Agenda Overview of Environmental Monitoring
More informationOverview and Introduction Annex 1 Revision
Overview and Introduction Annex 1 Revision Paul Moody, Inspector Pharmig Current Hot Topics in Pharmaceutical Microbiology, Dublin May 30 th, 2018 Scope History Process of Revision Rationale for Revision
More informationEU Guidance / Q&A. Greg McGurk, GMP Manager (acting) GMP Conference. 7 February 2017 Dublin
EU Guidance / Q&A Greg McGurk, GMP Manager (acting) GMP Conference 7 February 2017 Dublin TPN Manufacture Q&A TPN Guidance Proposed at IWG that working group be formed to draft guidance Several adverse
More informationAseptic Processing Current Issues & Trends
Aseptic Processing Current Issues & Trends 1 Introduction Richard M. Johnson Member, PDA for 20+ years President & CEO since 2009 Ladies and Gentlemen, I am happy to be here with you. Senhoras e Senhores,
More informationLUNCH AND LEARN. September 11, CE Activity Information & Accreditation
LUNCH AND LEARN Environmental Monitoring and Contamination Control September 11, 2015 Featured Speaker: Scott Sutton, Ph.D. The Microbiology Network N. Chili, New York 1 CE Activity Information & Accreditation
More informationResidue removal in Cleanroom Environments
Residue removal in Cleanroom Environments PDA Midwest Indianapolis Event 06 Oct 2016 Contamination Control Solutions 1/ BIO Beth Kroeger Technical Service Manager STERIS Life Sciences 4 years 24 years
More informationHow to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant
How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant Randy Hutt, Ph.D. Associate Director Sterility Assurance and Microbiology Luitpold
More informationEU GMP ANNEX 1 CHANGES CLARIFICATION AND IMPACT
1 EU GMP ANNEX 1 CHANGES CLARIFICATION AND IMPACT UNDERSTAND THE PROGRESSION OF REGULATORY THINKING AND HOW TO SUCCESSFULLY IMPLEMENT THE PROPOSED CHANGES BALTIMORE, MD MAY 6TH AND 7TH, 2019 UNIVERSITY
More informationA Case Study for an Improved Approach to Cleanroom Disinfection, Minimizing the Impact and Reducing Downtime
A Case Study for an Improved Approach to Cleanroom Disinfection, Minimizing the Impact and Reducing Downtime James Tucker Global Scientific Affairs Manager Ecolab Life Science A Case Study for an Improved
More informationThis compilation of the complex
Manufacturing in a Global Marketplace Reference Matrices on Regulations for Classified (Environmentally Controlled) Areas Betty Seawell, William Miele, and Jean Huxsoll The complex world of international
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationAseptic Process Validation
Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1 Overview Guidance Best Practices Common Deficiencies Slide 2 Aseptic
More informationValidation Needs for Sterilization by Aseptic Filtration
Validation Needs for Sterilization by Aseptic Filtration DCVMN Workshop, Hyderabad, 4-8 April 2016 Ramesh Raju Associate Director - Provantage Validation Services Overview Key Regulatory and Industry guidelines
More informationFDA s Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing - CGMPs Midwest FDC Conference November 4 2005 Susan Bruederle, Investigator FDA / ORA / Central Region Chicago District / Hinsdale IL FDA s Guidance
More informationEnvironmental Monitoring of Aseptic Processing Areas - 2
Environmental Monitoring of Aseptic Processing Areas - 2 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1 Active Air Monitoring (Viables) Air Sieve Samplers Draw air
More informationOn behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).
31 st March 2015 Submission of comments on ' Concept paper on the revision of annex 1 of the guidelines on good manufacturing practice manufacture of sterile medicinal products EMA/INS/GMP/735037/2014
More informationPreparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014
Preparing Your Aseptic Processing Facility for an FDA Inspection Valerie Welter, Director Quality Bayer HealthCare March 10, 2014 Agenda Regulatory Requirements Establishing your Approach Aseptic Controls
More informationManaging Your Environmental Isolates
Managing Your Environmental Isolates The Controversy Good practice includes the periodic challenge of prepared media with low levels of organisms. This includes USP indicator organisms as well as normal
More informationWebinar. The New EU-GMP Annex 1 draft Dupont. GOP-Innovations your Partner for Practical Training and e-learning. 8 June 2018
Webinar The New EU-GMP Annex 1 draft Dupont 8 June 2018 GOP-Innovations your Partner for Practical Training and e-learning Milenko Pavičić Pharmaceutical microbiologist, consultant, trainer, coach 10 years
More informationRegulatory Update. Paul Sexton. QP Forum
Regulatory Update Paul Sexton QP Forum 16 th April, 2015 Content Updates on GMP Guidance Updates on EU Legislation Draft Ph Eur monograph on WFI including RO 2 Chapter 5 - Production Paragraphs 27 to 30
More informationJulie Roberts. Audit hot Topics and Regulatory Requirements
Julie Roberts Audit hot Topics and Regulatory Requirements Overview Hot Topics Examples in warning letters Tips to detecting data integrity Recent changes in regulatory requirements Hot Topics Microbial
More informationSTERILE FILTRATION: PDA: A Global. Clarification Proposal Annex 1 Paragraph 113:
STERILE FILTRATION: PDA: A Global Clarification Proposal Annex 1 Paragraph 113: Focus Association on Pre-use/Poststerilization Integrity Testing Issue Paragraph 113: The integrity of the sterilised filter
More informationBest Practice in Environmental Monitoring
Best Practice in Environmental Monitoring Annette Grundy July 12 2016 1 Acknowledgement Dr Ed Tidswell previous roles at Baxter Senior Director R&D and Quality Director USP expert committee member Ed was
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationRobert Westney, M.S., RAC, CMQ/OE Director of Quality and Operations Cryologics, Inc. March 7, 2017
Robert Westney, M.S., RAC, CMQ/OE Director of Quality and Operations Cryologics, Inc. March 7, 2017 1 About the Presenter Bob Westney, M.S. QA/RA, RAC, CMQ/OE 30 years of industry experience QC Microbiology,
More informationOverview of a sterility assurance program for PET drugs
Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Overview of a sterility assurance program for PET drugs Eric Webster, PETNET Solutions Disclosures Employee of PETNET Solutions, a Siemens
More informationSupplementary Training Modules on Good Manufacturing Practice. Validation. WHO Technical Report Series, No. 937, Annex 4.
Supplementary Training Modules on Good Manufacturing Practice Validation WHO Technical Report Series, No. 937, 2006. Annex 4. Validation Slide 1 of 48 August 2006 Validation! Part 1. General overview on
More informationWebinar Expert Module 3: GMP Inspections Dupont
Webinar Expert Module 3: GMP Inspections Dupont 26 January & 9 February 2018 GOP-Innovations your Partner for Practical Training and e-learning Milenko Pavičić Pharmaceutical microbiologist, trainer, coach
More informationHVAC and Risk Management RACI Meeting 7 th December Agenda. Design. Project Management. Context. Qualification. Construction
HVAC and Risk Management RACI Meeting 7 th December 2011 Dr Stephen Firmer Asia Pacific Consultants Pty Ltd Agenda Context Project Management Design Construction Qualification Routine Control /Potential
More informationPoints to Consider for Aseptic Processing Part 2 May 2016
Points to Consider for Aseptic Processing Part 2 May 2016 PDA Points to Consider for Aseptic Processing Part 2 Task Force Authors and Contributors Harold Baseman, Valsource, LLC (Co-Chair) Gabriele Gori,
More informationCompounding Pharmacies and the Contract Testing Lab
Compounding Pharmacies and the Contract Testing Lab Scott Sutton, Ph.D. scott.sutton@microbiol.org 1 Disclaimer I am making this presentation as an independent agent I am not making this presentation as
More informationGeneral European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT
General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (16) 86 R2 MANAGEMENT OF ENVIRONMENTAL CONDITIONS Full document title and reference Document type Management of Environmental
More informationPDA: A Global. Association. Contamination Control: Particles, Bio-contamination, Aseptic manufacturing. PDA Parenteral 2014 Munich Conference
PDA Parenteral 2014 Munich Conference PDA: A Global Contamination Control: Particles, Bio-contamination, Bioburden Association and Endotoxins in Aseptic manufacturing. James Drinkwater F Ziel Head of Aseptic
More informationA risk based approach to managing environmental excursions
A risk based approach to managing environmental excursions RACI: Monitoring & protecting your GMP facility s Environment 20 th April Ngoc Anh-Thu Phan www.eurofins.com Content Introduction Risk Assessment
More informationTests to Support Sterility Claim. Imtiaz Ahmed
Tests to Support Sterility Claim Imtiaz Ahmed Sterile Product As per TGO 77, a sterile product must comply with the requirements of the following tests: Sterility Test Bacterial Endotoxins Test Appendix
More informationBioburden Contamination Control: A Holistic Overview
Bioburden Contamination Control: A Holistic Overview Scott Sutton, PhD Microbiology Network, Inc. Scott Sutton, PhD is the Principal of Microbiology Network, Inc (http:// microbiologynetwork.com/) a company
More informationBIO & PHARMA ANALYTICAL TECHNIQUES
BIO & PHARMA ANALYTICAL TECHNIQUES Chapter 11 by Dr. Siti Umairah Mokhtar Faculty of Engineering Technology umairah@ump.edu.my Chapter Description Aims Discuss theory, principles and application of analytical
More informationBiocontamination control in pharmaceutical production
White Paper Data Sheet Biocontamination control in pharmaceutical production and compliance to ISO 14698 with validated active microbial air samplers Tim Sandle, Ph.D., Head of Microbiology at Bio Products
More informationQualification of an Environmental Monitoring Program
[ Scott Sutton Qualification of an Environmental Monitoring Program Scott Sutton Microbiology Topics discusses various topics in microbiology of practical use in validation compliance. We intend this column
More informationDisinfectant Qualification A Multifaceted Study
Disinfectant Qualification A Multifaceted Study In this article, Ziva Abraham, Microrite, Inc., gives us a brief overview of the disinfectant qualification study process. An effective cleaning and disinfection
More informationBFS IOA BFS Training 2018 Kunming Qualification and Validation of a BFS-Installation including CIP/SIP
Qualification and Validation of a BFS-Installation including CIP/SIP Presented by Christoph Bohn and Stefan Kiesel Director Rommelag Pharma Service Senior Manager Rommelag Pharma Service Coyright BFS IOA
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015
Ref. Ares(2015)3808922-15/09/2015 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Medicinal Products Quality, Safety and Efficacy Brussels, [date] This document is for consultation until 11
More informationSterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM
Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management Overview Key Regulatory
More informationWhite Paper. Risk Management in Environmental Monitoring: Should you be spotting it sooner?
White Paper Risk Management in Environmental Monitoring: Should you be spotting it sooner? Executive Overview Quality Risk Management is a comparatively new approach in the pharmaceutical manufacturing
More informationDisinfectant Qualification Bacteria, Fungi, Viruses and Atypical Organisms A Step by Step Workshop
Microrite, Inc. brings you this unique advanced course in ; part of Microrite s Step by Step Workshop Series Participate in the only workshop which will guide you through the process of choosing a cost
More informationGuidance for Industry
Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Center for Drug Evaluation and Research (CDER) Center
More informationSemiconductor Manufacturing Facility Design
TM W W W. C E M A G. U S J U LY / A U G U S T 2 0 1 5 Semiconductor Manufacturing Facility Design Modular cleanrooms: An evolving industry ISO 14644 and biopharma monitoring Cleanrooms have a dirty little
More informationAseptic Processing Practices and Process Validation of Aseptic Operators
Aseptic Processing Practices and Process Validation of Aseptic Operators CBE Pty Ltd This training program is copyright to CBE Pty Ltd and may not be modified, reproduced, sold, loaned, hired or traded
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationPhEn-602 Notes # 4 J. Manfredi
PhEn-602 Notes # 4 J. Manfredi Spring 2009 1 Basic definitions Clean Room: A room in which the concentration of airborne particles is controlled and contains one or more clean zones Clean Zone: A defined
More informationCONTENTS About the Authors xiii 1 ENVIRONMENTAL MONITORING 1 Jeanne Moldenhauer Overview 1 Components of an Environmental Control System 2 Facility Design and Maintenance 3 Documentation Systems and Procedural
More informationValidation of Sterilizing Grade Filters
Validation of Sterilizing Grade Filters Presented by Laura Okhio-Seaman Sartorius Corporation 1 Sterilizing Grade Filters The definition of a sterilizing grade filter is one that will produce a sterile
More informationWhy Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services
Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and
More informationContamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC
Contamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC Contamination risk levels differ in aseptic, and non-sterile and terminally sterilized
More informationValidation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)
Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY!
More informationNHS QA Symposium, September 2013
1 www.pmtgb.com Germany - Benelux T o g e t h e r W e c r e a t e S o l u t i o n s France - Great Britain NHS QA Symposium, September 2013 John Cobb Microbiology Support Manager 2 www.pmtgb.com Germany
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationApplication of Quality Risk Management Tools for Cell Therapy Manufacturing
Application of Quality Risk Management Tools for Cell Therapy Manufacturing 17 th ISCT Annual Meeting May 20, 2011 Jean Stanton Associate Director, Product Quality Management Janssen Supply Chain Conflict/Disclaimer
More informationMedia Fill A Process Simution. Presented By Shikha Chauhan
Media Fill A Process Simution Presented By Shikha Chauhan 21 CFR 211.113 Validation of Aseptic Processing and Sterilization Process Simulation / Media Fill Filtration Efficacy Sterilization of Equipment,
More informationCOMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION
COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy, Chicago,
More informationUSP <1116> and Contamination
USP and Contamination Recovery Rates Scott Sutton ABSTRACT United States Pharmacopeia (USP) "Microbiological Control and Monitoring of Aseptic Processing Environments" approaches analysis
More informationDraft agreed by Quality Working Party 7 June Adopted by CHMP for release for consultation 28 June 2018
1 13 November 2018 2 EMA/CHMP/CVMP/QWP/496873/2018 3 4 Committee for Medicinal Products for Human Use (CHMP) 5 Committee for Medicinal Products for Veterinary Use (CVMP) 6 7 8 Draft Draft agreed by Quality
More informationUNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL CLEANROOMS
DEPARTMENT OF VETERANS AFFAIRS Veterans Health Administration Washington DC 20420 IL 10-2006-008 In Reply Refer To: 10NB UNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationTraining Prospectus Public Course Dates
Training Prospectus 2018 Public Course Dates Honeyman Group Assuring Compliance in Life Science Operating extensively within the global pharmaceutical, biotech, medical device and related healthcare industries,
More informationPDA: A Global. Association. Matrix Approach to Media Fills. (c) 2012 Catalent Pharma Solutions. All rights reserved.
PDA: A Global Matrix Approach to Media Fills Association (c) 2012 Catalent Pharma Solutions. All rights reserved. Overview Guidance Overview Matrix Introduction Why Matrix Media Fills Sample Matrix New
More informationRisk Based Environmental Monitoring (EM) and EM Data Management and Trending
Risk Based Environmental Monitoring (EM) and EM Data Management and Trending An Industry Roundtable Discussion Marsha Stabler Hardiman and Cheryl Zaman Zadeh November, 2015 PDA Metro Chapter Meeting Presenters
More informationFormulated Chemistries for Critical Environments
STERIS CORPORATION Formulated Chemistries for Critical Environments Superior Cleaning Products Backed by Proven Expertise Unique in critical environments......................... AND/OR REGULATORY CLAIMS
More informationEU GMP ANNEX 1 DRAFT CLARIFICATION AND IMPACT
1 EU GMP ANNEX 1 DRAFT CLARIFICATION AND IMPACT UNDERSTAND THE PROGRESSION OF REGULATORY THINKING AND HOW TO SUCCESSFULLY IMPLEMENT THE PROPOSED DOCUMENTED CONTAMINATION CONTROL STRATEGY SAN FRANCISCO,
More informationMicrobiological Cleaning Method Validation
Microbiological Cleaning Method Validation The purpose of cleaning procedures should never be to reduce bioburden to an acceptable level! Fergus O Connell QA Manager Eurofins ams Laboratories www.eurofins.com
More informationcompounding area based on environmental sampling and cleaning product type. Antiseptics and determine the appropriate use of each.
The pharmacist will be able to: 1. Determine a best practice for cleaning their compounding area based on environmental sampling and cleaning product type. 2. Discuss the difference between Disinfectants
More informationComplaints Investigations Root Cause Analysis
Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does
More informationINSPECTOR S OBSERVATIONS AND WARNING LETTER
Microrite, Inc. San Jose, CA, USA, http://www.microrite.com AIR VELOCITY MEASUREMENTS AND CORRELATION TO SMOKE STUDIES FOR ASEPTIC OPERATIONS KEYWORDS Air Velocity, Air Flows, Smoke Study, Air Pattern
More informationTECHNICAL LEAFLET. MEDI-MEDIA-FILL KIT SUPPLY PACKAGE (Code: MR-25/S)
TECHNICAL LEAFLET MEDI-MEDIA-FILL KIT SUPPLY PACKAGE (Code: MR-25/S) TEST AGAR PLATES FOR PERSONNEL AND ENVIRONMENTAL MICROBIOLOGICAL MONITORING COMPONENTS: Test Agar Plates Data Log Sheet Technical Leaflet
More informationCompounding Pharmacies and Water
Compounding Pharmacies and Water Scott Sutton, PhD scott.sutton@microbiol.org August 21, 2014 46 Disclaimer I am an independent consultant. I have been involved with USP for many years. I do not represent
More informationOverview of Inspection Issues with Legacy Products
Overview of Inspection Issues with Legacy Products Presented by Simone E. Pitts Consumer Safety Officer, USFDA Team Biologics simone.pitts@fda.hhs.gov Objective To provide some examples of recent inspectional
More informationValidation and Control of Porous Load Sterilisation
Validation and Control of Porous Load Sterilisation Crown Plaza Hotel, Santry; October 14 th 2010 Gerard Sheridan 14th October 2010 Slide 1 14th October 2010 Slide 2 14th October 2010 Slide 3 Overview
More informationManaging Your Environmental Isolates
Managing Your Environmental Isolates Good Testing Practices Good practice includes the periodic challenge of media with low levels of organisms. This includes USP indicator organisms as well as normal
More informationMicrobiology Research Associates
2017 Microbiology Research Associates List of Services www.mra-bact.com 33 Nagog Park Acton, MA 01720 978.263.2624 Page 1 of 11 Microbiology Tests Pharma/Biotech/Medical Devices Time From Sample Receipt
More informationDisinfection Qualification Testing
Disinfection Qualification Testing Considerations for Aseptic & Cleanroom Manufacturing Environments White Paper Considerations for Aseptic and Cleanroom Manufacturing Environments Obtaining the highest
More informationTechnical Report No. 70 Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities
Technical Report No. 70 Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities PDA Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities
More informationPublished Standards ISO General instructions for microbiological examination ISO Enumeration and detection of aerobic mesophilic bacteri
ISO Standards Cosmetics Microbiology TC 217 WG1 Joyce Beauchamp L OREAL USA Products, Inc. 2010 PCPC Microbiology Workshop ISO TC 217 WG1 Microbiological standards and limits Secretariat IRISI Secretary
More informationT H E P R O P O S A L F O R T H E Y E A R
Training T H E P R O P O S A L F O R T H E Y E A R 2 0 1 9 Our GMP courses combine a convenient format with an effective, interactive learning experience. To maximize and customize your professional development.
More informationMINIMUM REQUIREMENTS FOR A VENDOR
MINIMUM REQUIREMENTS FOR A VENDOR When outsourcing the production of sterile products the first step in vendor evaluation is to see if they meet the minimum requirements. We ve developed a group of questions
More informationGMP for ATMP should be a document annexed to standard GMP (a new Annex) and not a stand-alone document.
Leem comments on Commission proposal for Good Manufacturing Practice for Advanced Therapy Medicinal Products 1. General comments Line number(s) of the relevant text General comment
More informationThe Application of Pharmaceutical cgmp to Live Bacterial Products. James Harris Business Development Manager
The Application of Pharmaceutical cgmp to Live Bacterial Products James Harris Business Development Manager The Objective CMC expectations of a cgmp live bacterial biopharmaceutical project Overview Define
More informationMicrobiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A
USP Antimicrobial Effectiveness Testing Microbiology Testing: Webinar Q&A 1. If a base ingredient is designed for the purpose of compounding a specific type of preparation does this forgo the necessity
More informationLow Temperature Processing. An Update on Guidelines, Standards and Requirements
Low Temperature Processing An Update on Guidelines, Standards and Requirements Continuing Education Contact Hours Participants must complete the entire presentation/seminar to achieve successful completion
More informationDISINFECTION QUALIFI CATION TESTING CONSIDERATIONS FOR THE ASEPTIC AND CLEANROOM MANUFACTURING ENVIRONMENT
DISINFECTION QUALIFI CATION TESTING CONSIDERATIONS FOR THE ASEPTIC AND CLEANROOM MANUFACTURING ENVIRONMENT by Dave Rottjakob, M.T. (ASCP) December, 2013 INTRODUCTION Obtaining the highest confidence that
More informationManual 042 Water Quality Standard
1 Purpose Manual 042 Quality Standard To describe the quality standards required for the production, distribution, use and testing of water used in the manufacture of manufactured materials. 2 Scope and
More informationCurrent Industry Trends -Including Cleaning and Disinfection trends, Disinfectant Validation Trends, and Current Warning Letter Activity.
Current Industry Trends -Including Cleaning and Disinfection trends, Disinfectant Validation Trends, and Current Warning Letter Activity. Jim Polarine Jr. MA. Technical Service Manager Steris Corp. Copyright
More informationPharmaceutical Compounding Sterile and Nonsterile Preparations. Jeanne Sun, PharmD
Pharmaceutical Compounding Sterile and Nonsterile Preparations Jeanne Sun, PharmD Agenda Legal Framework Overview Pharmaceutical Compounding Nonsterile Preparations Pharmaceutical Compounding
More informationComments from: 1. General comments. International Plasma Fractionation Association (IPFA) Our ref. IP
Submission of comments on Commission proposal for Good Manufacturing Practice for Advanced Therapy Medicinal Products Comments from: Name of organisation or individual International
More informationCompounding Pharmacies and the USP <71> Sterility Tests
Compounding Pharmacies and the USP Sterility Tests Scott Sutton, Ph.D. scott.sutton@microbiol.org 49 41 Disclaimer I am making this presentation as an independent agent I am not making this presentation
More informationIndustry Case Study: A Microbial Investigation of Contamination by Burkholderia multivorans. Jim Klein and Geert Verdonk Merck & Co., Inc.
Industry Case Study: A Microbial Investigation of Contamination by Burkholderia multivorans Jim Klein and Geert Verdonk Merck & Co., Inc. Messages The role of microbiological analysis The role of subject
More informationImplementation of Enhanced Active Air Particle Counting. Jeffrey W. Weber Kalamazoo, MI May 5, 2015 PDA Midwest
Implementation of Enhanced Active Air Particle Counting Jeffrey W. Weber Kalamazoo, MI May 5, 2015 PDA Midwest Agenda Introduction Regulatory Aspects Case Study: Investigation Future Role: Elimination
More informationGMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More informationProcess Validation Guidelines. by Pramote Cholayudth Thai Industrial Pharmacist Association (TIPA)
Process Validation Guidelines by Pramote Cholayudth cpramote2000@yahoo.com Thai Industrial Pharmacist Association (TIPA) September 19, 2016 1 2 Process Validation References Hierarchy Law Regulatory Guidelines
More information